FDA approves second generic mifepristone amid GOP pressure

The FDA approved Evita, a second generic version of mifepristone (the primary abortion pill), on October 2, 2025, expanding access to medication abortion. The approval came despite ongoing Republican congressional efforts to withdraw the drug's approval entirely and active pressure on the FDA from anti-abortion groups. The generic approval was expected to lower costs and expand access through mail-order pharmacy networks.